Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
ExonHit Therapeutics
ExonHit Therapeutics
Activities:
Regulatory
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part I
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
Resolving capping issues in tablet manufacturing
Natoli explores the various causes of capping and the methods to prevent it
Effective ways to optimise heat exchangers
Heat exchangers are used within a wide range of process industries as a way to transfer heat between two fluid streams across a medium in an energy conservative way
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Upcoming event
Lounges
23-25 April 2024 | Conference | Messe Karlsruhe, Germany
See all
Related Content
Research & Development
Erytech Pharma to lead TEDAC project
Will receive OSEO funding of €10.7m to develop personalised medicines to treat cancer
Research & Development
Exonhit receives EU grant of €418,000
Brings novel biomarker tests to Responsify project focused on personalised medicine in cancer
Analysis
Almac to perform the analytic phase of AclarusDx for Exonhit
Almac will perform the test from its ISO17025 accredited laboratory
Research & Development
Drug licensing deals in 2010
Big pharma companies have been busy filling the yawning gaps in their product pipelines by licensing drugs developed by smaller biotechnology firms. Dr Sarah Houlton outlines a selection of the deals done this year
Research & Development
ExonHit and BioMerieux end colon cancer collaboration
The partners say the clinical data did not reach the required level of performance.
Subscribe now